- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Batch of Tofajak Tablets earlier classified as NSQ now flagged as Spurious

New Delhi: Through a recent revised drug alert, the Central Drugs Standard Control Organization (CDSCO) has classified a batch of Tofacitinib Tablets IP 5 mg (TOFAJAK TABLETS) as spurious. The batch was earlier classified as Not of Standard Quality (NSQ).
The Medical Dialogues team had reported that 41 drug formulations were declared as Not of Standard Quality (NSQ) in November 2024, based on testing conducted by various CDSCO laboratories. Among these was a batch of Tofacitinib Tablets IP 5 mg (TOFAJAK TABLETS) (Batch No. 4F30009), listed under Cipla LTD , which was flagged by the Regional Drugs Testing Laboratory (RDTL) Chandigarh for failing identification and assay of Tofacitinib citrate calculated as Tofacitinib.
However, the same batch has now also been classified as “purportedly spurious” in CDSCO’s revised alert, with Cipla informing that it did not manufacture this batch.
The batch in question — Batch No. 4F30009, with a manufacturing date of May 2024 and expiry of April 2026 — carries Cipla’s name on the label. However, the company has officially clarified that it did not manufacture this particular batch.
'The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and that it is a spurious drug.' the CDSCO stated in its revised alert.
The matter is now under active investigation. While the product is currently listed as “purportedly spurious,” the final classification will depend on the outcome of the ongoing inquiry.
Drug Alert for the Month of November–2024 (Revised)
List of Drugs, Medical Devices, Vaccines and Cosmetics declared as Not of Standard Quality/Spurious/Adulterated/Misbranded for the Month of November–2024 (Revised)
S. No | Name of Drugs/medical device/cosmetics | Batch No. | Date of Manufacture | Date of Expiry | Manufactured by | Reason for failure | Drawn By | Firms’s reply | Remarks |
40. | Tofacitinib Tablets IP 5 mg (TOFAJAK TABLETS) | 4F30009 | 05/2024 | 04/2026 | Under Investigation | Identification and Assay of Tofacitinib citrate calculated as Tofacitinib | Drugs Control Officer, Gurugram | The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and that it is a spurious drug. | The product is purported to be spurious; however, the same is subject to outcome of investigation. |
Also Read:Cipla gets CDSCO Panel nod to study Revefenacin Inhalation solution
To view the official notice, click the link below:
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751